log in
Print | Back

Haynes and Boone, LLP

Suzanne A. Trigg

Suzanne A. Trigg

Partner

Haynes and Boone, LLP
Texas, U.S.A.

tel: +1 214 651 5098
Send an Email

Local Time: Sun. 23:19

Profile
Suzie Trigg guides companies through FDA regulatory matters, high-stakes supply chain transactions, and strategic growth. She leverages her unique experience to help companies negotiate and document transactions and make well-informed decisions to address their complex FDA regulatory requirements. She holds leadership positions in the firm's Healthcare and Life Sciences Practice Group, and its Food, Beverage and Restaurant Practice Group.

Suzie is a go-to lawyer for companies tackling critical supply chain challenges, having been lead outside counsel for, among others, a 7,500+ store retailer negotiating supply chain agreements for transactions valued at more than $25 billion over five years. Her recent work also includes:

Facilitating investigations and analyses of high-stakes food safety and other product concerns, including both preventive gap analyses and analyzing specific events to determine FDA regulatory obligations and to chart a long-term course of action to correct and prevent re-occurrence of the potential concerns

Preparing and implementing supplier standards and supply chain agreements for multiple global restaurant chains

Developing and negotiating commercial agreements and quality agreements for the manufacture, supply, and distribution of both branded and private label foods, cosmetics, dietary supplements, and over-the-counter drugs

Suzie helps companies lawfully market their products by reviewing the use of specific ingredients and by reviewing product claims made on labels or in advertising. Her experience in this area includes foods, dietary supplements, cosmetics, personal care products, and over-the-counter drugs. She frequently provides advice and guidance on strategies intended to reduce the risk of a demand, class action, or regulatory enforcement.

While much of her work focuses on designing strategies to minimize risk and avoid costly delays or setbacks, Suzie also helps companies thoroughly and efficiently address obstacles, such as potential FDA enforcement actions, potential product recalls, and disputes with distributors or other supply chain partners.

Given Suzie's experience, she often leads due diligence of FDA regulated companies in connection with a potential merger or acquisition and addresses issues critical to deal closure. Suzie has also conducted due diligence for potential underwriters of securities offerings by emerging pharmaceutical, medical device, and biologic companies.

Suzie is in her third year of serving on FDLI's Food Advertising and Litigation Conference Planning Committee. She previously served on FDLI's Food and Dietary Supplements Committee and FDLI's Writing Awards Committee.

Bar Admissions

Texas, 2006

Education

J.D., University of Texas at Austin School of Law, 2006, with honors, Texas Environmental Law Journal
B.S., Animal Science, Texas A&M University, 2003
Areas of Practice
Articles

It's Still Gray: The 2018 Farm Bill and the Legality of CBD Under Federal Law
Haynes and Boone, LLP, January 2019

President Trump recently signed the Agriculture Improvement Act of 2018 (also known as the 2018 Farm Bill) and the cannabis industry quickly and widely celebrated passage as clearing the way to sell products containing cannabidiol (better known as CBD). But is it really? As one might expect, this lawyer’s answer is that “it depends.”CBD has become known for its purported health benefits in relation to a wide range of conditions...

The IP Beacon, April 2018
Haynes and Boone, LLP, April 2018

View the PDF version of the April 2018 IP Beacon. Are Works Generated by AI Subject to IP Protection? When Philip Dick wrote the 1968 novel "Do Androids Dream of Electric Sheep?," the inspiration for the 1982 film "Blade Runner," artificial intelligence was more fiction than science. Fifty years later, theHarvard Business Reviewpredicts that AI will be the single biggest technological development of our era, as transformative as the steam engine or electricity...

Health Law Vitals - A Healthcare Newsletter from Haynes and Boone, March 2018
Haynes and Boone, LLP, March 2018

 More than two and a half years after the U.S. Food and Drug Administration (FDA) announced that it was reevaluating its regulatory framework for homeopathic products, the FDA released its Draft Guidance on Drug Products Labeled as Homeopathic. The Draft Guidance summarizes the FDA’s current enforcement perspective on homeopathic products and provides a list of the FDA’s enforcement priorities.The bills reawakened a debate about the pros and cons of POHs...

WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2019